Indian FDA wants to increase use of generics

Genéricos/General | Posted 03/05/2013 post-comment0 Post your comment

The Commissioner of Indian Food and Drug Administration (FDA) has denied allegations by physicians and pharmacists in India that the bioavailability of generic drugs is doubtful.

picture47

Bioavailability is the fraction of an administered dose of drug that reaches the systemic circulation unchanged.

Commissioner Mahesh Zagade said that ‘these are excuses to deny people their right[s] to get medicines at rational prices’. He added that there was also no evidence that the bioavailability content in brand-name medicines was ‘[up] to the mark’. He noted that many large pharmaceutical companies outsourced production of their drugs to the same contractors used for the production of generics, and that this did not mean that these products were ‘substandard or less effective’.

The Commissioner has also urged the Indian Government to require that physicians add a line to prescriptions noting that generics or other cheaper versions are available.

India supplies 20% of all generics globally, exporting to more than 200 countries worldwide. It is therefore important to get the domestic market for generics right and recent governmental policies have been aimed at encouraging growth in the use of generics [1].

Related article

Domestic Indian market spawns generic agreements

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. India supplies 20% of generic drugs worldwide [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 3]. Available from: www.gabionline.net/Reports/India-supplies-20-of-generic-drugs-worldwide

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

comment icon Comments (0)
Post your comment
Related content
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Genéricos/General Posted 23/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010